Related Experiment Video
Updated: May 24, 2025
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
22.7K
Adjunct botulinum toxin for cicatricial pemphigoid.
Frank Mei1, Liane O Dallalzadeh1, Preston Choi1
1Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Orbit (Amsterdam, Netherlands)
|February 28, 2025
Summary
Botulinum toxin-A injections offer temporary relief for cicatricial entropion in patients with pemphigoid. This treatment improved ocular irritation and eyelid margin position during active conjunctivitis.
Area of Science:
- Ophthalmology
- Dermatology
Background:
- Pemphigoid can cause cicatricial changes in the conjunctiva, leading to entropion and trichiasis.
- These changes can result in limbal stem cell deficiency and corneal damage.
Purpose of the Study:
- To evaluate botulinum toxin-A as a temporizing treatment for lower eyelid cicatricial entropion in patients with active cicatrizing conjunctivitis.
Main Methods:
- A case series of three patients treated with botulinum toxin-A for lower eyelid cicatricial entropion.
- Patients received serial injections during active conjunctivitis phases.
Main Results:
- All patients reported subjective improvement in ocular irritation.
- Eyelid margin position improved, with decreased orbicularis override and better lash trajectory.
- No pemphigoid exacerbation occurred; patients opted for repeat injections.
Conclusions:
- Botulinum toxin-A is an effective temporizing treatment for cicatricial entropion when surgery is contraindicated.
- It provides symptomatic relief and improves eyelid function during active inflammation.
More Related Videos
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
648
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
648
01:31Skeletal Muscle Relaxants: Therapeutic Uses
457
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
457
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
663
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
663
01:19Depolarizing Blockers: Pharmocokinetics
300
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
300
01:20Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
383
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
383